These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12559512)

  • 61. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
    Jeffery DR; Chepuri N; Durden D; Burdette J
    Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
    Millefiorini E; Gasperini C; Pozzilli C; D'Andrea F; Bastianello S; Trojano M; Morino S; Morra VB; Bozzao A; Calo' A; Bernini ML; Gambi D; Prencipe M
    J Neurol; 1997 Mar; 244(3):153-9. PubMed ID: 9050955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
    Wawrzyniak S; Rzepiński Ł
    Neurol Neurochir Pol; 2020; 54(1):54-61. PubMed ID: 31922582
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients.
    Montú MB; Arruda WO; de Oliveira Mde S; Ramina R
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):225-7. PubMed ID: 16100967
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis.
    De Castro S; Cartoni D; Millefiorini E; Funaro S; Gasperini C; Morino S; Tallarico D; Beni S
    J Clin Pharmacol; 1995 Jun; 35(6):627-32. PubMed ID: 7665724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Gonsette R; Debouverie M; Sindic C; Ferré JC; Edan G
    Mult Scler; 2016 May; 22(6):817-21. PubMed ID: 26286699
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.
    Hellwig K; Schimrigk S; Lukas C; Hoffmann V; Brune N; Przuntek H; Müller T
    Clin Neuropharmacol; 2006; 29(5):286-91. PubMed ID: 16960474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High dose biotin as treatment for progressive multiple sclerosis.
    Birnbaum G; Stulc J
    Mult Scler Relat Disord; 2017 Nov; 18():141-143. PubMed ID: 29141796
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
    Avasarala JR; Cross AH; Clifford DB; Singer BA; Siegel BA; Abbey EE
    Mult Scler; 2003 Feb; 9(1):59-62. PubMed ID: 12617270
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
    Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
    Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.